S&P 500   4,584.49 (+1.58%)
DOW   34,688.52 (+1.96%)
QQQ   389.66 (+0.66%)
AAPL   163.13 (-1.00%)
MSFT   330.76 (+0.21%)
FB   308.90 (-0.55%)
GOOGL   2,864.00 (+1.52%)
AMZN   3,441.64 (-0.06%)
TSLA   1,079.24 (-1.44%)
NVDA   321.34 (+2.22%)
BABA   121.09 (-1.14%)
NIO   35.33 (-7.78%)
CGC   9.95 (+0.10%)
AMD   150.18 (+0.72%)
GE   95.01 (+2.16%)
MU   83.11 (-2.40%)
T   23.11 (+3.96%)
F   19.81 (+1.17%)
DIS   146.39 (+2.98%)
PFE   53.61 (-1.96%)
AMC   29.37 (+2.80%)
ACB   5.95 (-1.00%)
BA   198.45 (+5.45%)
S&P 500   4,584.49 (+1.58%)
DOW   34,688.52 (+1.96%)
QQQ   389.66 (+0.66%)
AAPL   163.13 (-1.00%)
MSFT   330.76 (+0.21%)
FB   308.90 (-0.55%)
GOOGL   2,864.00 (+1.52%)
AMZN   3,441.64 (-0.06%)
TSLA   1,079.24 (-1.44%)
NVDA   321.34 (+2.22%)
BABA   121.09 (-1.14%)
NIO   35.33 (-7.78%)
CGC   9.95 (+0.10%)
AMD   150.18 (+0.72%)
GE   95.01 (+2.16%)
MU   83.11 (-2.40%)
T   23.11 (+3.96%)
F   19.81 (+1.17%)
DIS   146.39 (+2.98%)
PFE   53.61 (-1.96%)
AMC   29.37 (+2.80%)
ACB   5.95 (-1.00%)
BA   198.45 (+5.45%)
S&P 500   4,584.49 (+1.58%)
DOW   34,688.52 (+1.96%)
QQQ   389.66 (+0.66%)
AAPL   163.13 (-1.00%)
MSFT   330.76 (+0.21%)
FB   308.90 (-0.55%)
GOOGL   2,864.00 (+1.52%)
AMZN   3,441.64 (-0.06%)
TSLA   1,079.24 (-1.44%)
NVDA   321.34 (+2.22%)
BABA   121.09 (-1.14%)
NIO   35.33 (-7.78%)
CGC   9.95 (+0.10%)
AMD   150.18 (+0.72%)
GE   95.01 (+2.16%)
MU   83.11 (-2.40%)
T   23.11 (+3.96%)
F   19.81 (+1.17%)
DIS   146.39 (+2.98%)
PFE   53.61 (-1.96%)
AMC   29.37 (+2.80%)
ACB   5.95 (-1.00%)
BA   198.45 (+5.45%)
S&P 500   4,584.49 (+1.58%)
DOW   34,688.52 (+1.96%)
QQQ   389.66 (+0.66%)
AAPL   163.13 (-1.00%)
MSFT   330.76 (+0.21%)
FB   308.90 (-0.55%)
GOOGL   2,864.00 (+1.52%)
AMZN   3,441.64 (-0.06%)
TSLA   1,079.24 (-1.44%)
NVDA   321.34 (+2.22%)
BABA   121.09 (-1.14%)
NIO   35.33 (-7.78%)
CGC   9.95 (+0.10%)
AMD   150.18 (+0.72%)
GE   95.01 (+2.16%)
MU   83.11 (-2.40%)
T   23.11 (+3.96%)
F   19.81 (+1.17%)
DIS   146.39 (+2.98%)
PFE   53.61 (-1.96%)
AMC   29.37 (+2.80%)
ACB   5.95 (-1.00%)
BA   198.45 (+5.45%)
NASDAQ:SAGE

Sage Therapeutics Stock Forecast, Price & News

$37.51
+0.36 (+0.97%)
(As of 12/2/2021 01:43 PM ET)
Add
Compare
Today's Range
$36.54
$37.91
50-Day Range
$37.15
$47.11
52-Week Range
$37.05
$98.39
Volume
6,383 shs
Average Volume
606,692 shs
Market Capitalization
$2.21 billion
P/E Ratio
3.00
Dividend Yield
N/A
Beta
1.76
30 days | 90 days | 365 days | Advanced Chart
Receive SAGE News and Ratings via Email

Sign-up to receive the latest news and ratings for Sage Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Sage Therapeutics logo

About Sage Therapeutics

SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey on April 16, 2010 and is headquartered in Cambridge, MA.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SAGE
Employees
298
Year Founded
N/A

Sales & Book Value

Annual Sales
$1.11 billion
Book Value
$31.16 per share

Profitability

Net Income
$606.07 million
Pretax Margin
57.61%

Debt

Price-To-Earnings

Miscellaneous

Free Float
56,139,000
Market Cap
$2.21 billion
Optionable
Optionable

Company Calendar

Last Earnings
11/02/2021
Today
12/02/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
2/23/2022

MarketRank

Overall MarketRank

2.54 out of 5 stars

Medical Sector

91st out of 1,392 stocks

Pharmaceutical Preparations Industry

37th out of 669 stocks

Analyst Opinion: 4.2Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -












Sage Therapeutics (NASDAQ:SAGE) Frequently Asked Questions

Is Sage Therapeutics a buy right now?

17 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sage Therapeutics in the last year. There are currently 10 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Sage Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SAGE, but not buy additional shares or sell existing shares.
View analyst ratings for Sage Therapeutics
or view top-rated stocks.

How has Sage Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

Sage Therapeutics' stock was trading at $42.30 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, SAGE shares have decreased by 11.3% and is now trading at $37.51.
View which stocks have been most impacted by COVID-19
.

When is Sage Therapeutics' next earnings date?

Sage Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, February 23rd 2022.
View our earnings forecast for Sage Therapeutics
.

How were Sage Therapeutics' earnings last quarter?

Sage Therapeutics, Inc. (NASDAQ:SAGE) released its earnings results on Tuesday, November, 2nd. The biopharmaceutical company reported ($2.21) earnings per share for the quarter, missing the consensus estimate of ($1.84) by $0.37. Sage Therapeutics had a negative trailing twelve-month return on equity of 23.76% and a net margin of 57.61%. During the same period last year, the firm posted ($2.03) earnings per share.
View Sage Therapeutics' earnings history
.

What price target have analysts set for SAGE?

17 brokers have issued twelve-month price targets for Sage Therapeutics' shares. Their forecasts range from $44.00 to $100.00. On average, they anticipate Sage Therapeutics' share price to reach $70.63 in the next year. This suggests a possible upside of 88.3% from the stock's current price.
View analysts' price targets for Sage Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Sage Therapeutics' key executives?

Sage Therapeutics' management team includes the following people:
  • Barry E. Greene, President, Chief Executive Officer & Director (LinkedIn Profile)
  • Kimi E. Iguchi, Chief Financial Officer & Treasurer
  • Al Robichaud, Chief Scientific Officer
  • Jim Doherty, Chief Research Officer
  • Amy Schacterle, Senior VP-Research & Development Strategy

What other stocks do shareholders of Sage Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sage Therapeutics investors own include NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Alibaba Group (BABA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Netflix (NFLX), Roku (ROKU), QUALCOMM (QCOM) and Bristol-Myers Squibb (BMY).

What is Sage Therapeutics' stock symbol?

Sage Therapeutics trades on the NASDAQ under the ticker symbol "SAGE."

Who are Sage Therapeutics' major shareholders?

Sage Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Wellington Management Group LLP (11.49%), Bellevue Group AG (5.45%), BlackRock Inc. (4.88%), Janus Henderson Group PLC (1.78%), Geode Capital Management LLC (1.49%) and Point72 Asset Management L.P. (1.29%). Company insiders that own Sage Therapeutics stock include Albert Robichaud, Barry E Greene, Barry E Greene, James M Frates and Jeffrey M Jonas.
View institutional ownership trends for Sage Therapeutics
.

Which major investors are selling Sage Therapeutics stock?

SAGE stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Invesco Ltd., Jane Street Group LLC, Caption Management LLC, Morgan Stanley, Citadel Advisors LLC, Two Sigma Advisers LP, and Dimensional Fund Advisors LP.
View insider buying and selling activity for Sage Therapeutics
or view top insider-selling stocks.

Which major investors are buying Sage Therapeutics stock?

SAGE stock was purchased by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Bellevue Group AG, Point72 Asset Management L.P., Asymmetry Capital Management L.P., The Manufacturers Life Insurance Company , Geode Capital Management LLC, Pinnacle Associates Ltd., and Integral Health Asset Management LLC. Company insiders that have bought Sage Therapeutics stock in the last two years include Albert Robichaud, Barry E Greene, James M Frates, and Jeffrey M Jonas.
View insider buying and selling activity for Sage Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Sage Therapeutics?

Shares of SAGE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sage Therapeutics' stock price today?

One share of SAGE stock can currently be purchased for approximately $37.51.

How much money does Sage Therapeutics make?

Sage Therapeutics has a market capitalization of $2.21 billion and generates $1.11 billion in revenue each year. The biopharmaceutical company earns $606.07 million in net income (profit) each year or $12.51 on an earnings per share basis.

How many employees does Sage Therapeutics have?

Sage Therapeutics employs 298 workers across the globe.

What is Sage Therapeutics' official website?

The official website for Sage Therapeutics is www.sagerx.com.

Where are Sage Therapeutics' headquarters?

Sage Therapeutics is headquartered at 215 FIRST STREET, CAMBRIDGE MA, 02142.

How can I contact Sage Therapeutics?

Sage Therapeutics' mailing address is 215 FIRST STREET, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at (617) 299-8380, via email at [email protected], or via fax at 617-299-8379.


This page was last updated on 12/2/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.